Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | ITK | Q08881 | 13/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637613 | 0.91 | CHEK1 (0.53) | CHEK1ITKTRPA1MAP2K4 | |
| SCHEMBL142647 | 0.88 | CHEK1 (0.52) | CHEK1ITKTRPA1MAP2K4PTGS2 | |
| SCHEMBL5635710 | 0.82 | CHEK1 (0.54) | CHEK1ITK | |
| SCHEMBL143964 | 0.82 | ITK (0.70) | CHEK1ITKTRPA1 | |
| SCHEMBL147603 | 0.79 | ITK (0.66) | CHEK1ITKTRPA1MAP2K4 | |
| SCHEMBL5636233 | 0.79 | ITK (0.53) | CHEK1ITKMAP2K4 | |
| SCHEMBL144764 | 0.78 | MAP2K4 (0.65) | CHEK1ITKTRPA1MAP2K4 | |
| SCHEMBL142590 | 0.77 | ITK (0.73) | CHEK1ITK | |
| SCHEMBL146998 | 0.77 | CHEK1 (0.74) | CHEK1 | |
| SCHEMBL144396 | 0.76 | MAP2K4 (0.68) | CHEK1ITKTRPA1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | CHEK1 3154/4885ITK 2496/4885TRPA1 4439/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | CHEK1 3154/4885ITK 2496/4885TRPA1 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.